• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Could Molnupiravir Be the First-Line Alternative Oral Antiviral Agent for COVID-19 Patients at High Risk?莫努匹韦能否成为高危COVID-19患者的一线替代口服抗病毒药物？
J Korean Med Sci. 2024 Feb 19;39(6):e74. doi: 10.3346/jkms.2024.39.e74.
2
Covid-19: What is the evidence for the antiviral molnupiravir?新冠病毒：抗新冠病毒药物莫努匹拉韦的证据有哪些？
BMJ. 2022 Apr 13;377:o926. doi: 10.1136/bmj.o926.
3
Molnupiravir for treatment of COVID-19.莫努匹韦用于治疗新型冠状病毒肺炎。
Med Lett Drugs Ther. 2022 Jan 24;64(1642):10-11.
4
Additional analyses support superior efficacy of nirmatrelvir/ritonavir over molnupiravir for COVID-19.进一步分析表明，对于新冠病毒病，奈玛特韦/利托那韦比莫努匹韦疗效更佳。
J Med Virol. 2024 Feb;96(2):e29464. doi: 10.1002/jmv.29464.
5
Two short approaches to the COVID-19 drug β-D--hydroxycytidine and its prodrug molnupiravir.两种合成 COVID-19 药物 β-D--羟基胞苷及其前药莫努匹韦的简洁方法。
Org Biomol Chem. 2024 Jan 24;22(4):735-740. doi: 10.1039/d3ob02039h.
6
Comprehensive review on molnupiravir in COVID-19: a novel promising antiviral to combat the pandemic.关于莫努匹韦在 COVID-19 中的全面综述：一种新型有前途的抗病毒药物，以对抗这一大流行病。
Future Microbiol. 2022 Mar;17(5):377-391. doi: 10.2217/fmb-2021-0252. Epub 2022 Feb 24.
7
Molnupiravir in COVID-19: A systematic review of literature.莫努匹韦治疗 COVID-19：文献系统评价。
Diabetes Metab Syndr. 2021 Nov-Dec;15(6):102329. doi: 10.1016/j.dsx.2021.102329. Epub 2021 Oct 30.
8
Antiviral Efficacy of Molnupiravir for COVID-19 Treatment.莫努匹韦治疗 COVID-19 的抗病毒疗效。
Viruses. 2022 Apr 6;14(4):763. doi: 10.3390/v14040763.
9
Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study.阿兹夫定、莫努匹韦和奈玛特韦/利托那韦在轻中度 COVID-19 成年患者中的比较：一项回顾性队列研究。
Sci Rep. 2024 Feb 9;14(1):3318. doi: 10.1038/s41598-024-53862-y.
10
An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19.关于莫努匹韦的使用的最新实用指南，以及与具有治疗 COVID-19 的紧急使用授权的药物的比较。
Diabetes Metab Syndr. 2022 Feb;16(2):102396. doi: 10.1016/j.dsx.2022.102396. Epub 2022 Jan 13.

本文引用的文献

1
Determining and Comparing the Real-World Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Patients Hospitalized With COVID-19.确定并比较莫努匹拉韦和奈玛特韦-利托那韦对新冠病毒肺炎住院患者的实际疗效。
J Korean Med Sci. 2024 Feb 19;39(6):e52. doi: 10.3346/jkms.2024.39.e52.
2
Effectiveness and Adverse Events of Nirmatrelvir/Ritonavir Versus Molnupiravir for COVID-19 in Outpatient Setting: Multicenter Prospective Observational Study.奈玛特韦/利托那韦与莫努匹韦在门诊环境下用于 COVID-19 的有效性和不良事件：多中心前瞻性观察研究。
J Korean Med Sci. 2023 Oct 30;38(42):e347. doi: 10.3346/jkms.2023.38.e347.
3
Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Hospitalized Patients With COVID-19 : A Target Trial Emulation Study.莫努匹韦和奈玛特韦-利托那韦在 COVID-19 住院患者中的疗效：一项目标试验模拟研究。
Ann Intern Med. 2023 Apr;176(4):505-514. doi: 10.7326/M22-3057. Epub 2023 Mar 14.
4
PANORAMIC: important insights into molnupiravir use in COVID-19.全景报道：关于莫努匹拉韦用于治疗新冠肺炎的重要见解。
Lancet. 2023 Jan 28;401(10373):250-251. doi: 10.1016/S0140-6736(22)02593-4. Epub 2022 Dec 22.
5
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial.莫努匹韦联合常规治疗与单纯常规治疗用于 COVID-19 高风险不良结局成人患者早期治疗的比较（PANORAMIC）：一项开放标签、平台适应性随机对照试验。
Lancet. 2023 Jan 28;401(10373):281-293. doi: 10.1016/S0140-6736(22)02597-1. Epub 2022 Dec 22.
6
Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study.奥密克戎 BA.2 波期间香港住院的 COVID-19 患者无入院时吸氧需求的患者中早期莫努匹韦或奈玛特韦-利托那韦的真实世界疗效：一项回顾性队列研究。
Lancet Infect Dis. 2022 Dec;22(12):1681-1693. doi: 10.1016/S1473-3099(22)00507-2. Epub 2022 Aug 24.
7
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.莫努匹韦片用于非住院 COVID-19 患者的口服治疗。
N Engl J Med. 2022 Feb 10;386(6):509-520. doi: 10.1056/NEJMoa2116044. Epub 2021 Dec 16.
8
Covid-19: Pfizer's paxlovid is 89% effective in patients at risk of serious illness, company reports.新冠病毒：辉瑞公司报告称，其新冠口服药帕罗韦德对有重症风险的患者有效率达89%。
BMJ. 2021 Nov 8;375:n2713. doi: 10.1136/bmj.n2713.

Could Molnupiravir Be the First-Line Alternative Oral Antiviral Agent for COVID-19 Patients at High Risk?

作者信息

Lee Ji Yong

机构信息

Division of Infectious Disease, Department of Internal Medicine, Gumdan Top Hospital, Incheon, Korea.

出版信息

J Korean Med Sci. 2024 Feb 19;39(6):e74. doi: 10.3346/jkms.2024.39.e74.

DOI:10.3346/jkms.2024.39.e74
PMID:38374633
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10876427/
Abstract
摘要